# EDGAR Filing Document

**Accession Number:** 0001873875
**File Stem:** 0001213900-25-067336
**Filing Date:** 2025-7
**Character Count:** 33375
**Document Hash:** 1b0743ad8b72de896bd6805987fdf85d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-067336.hdr.sgml**: 20250724

**ACCESSION NUMBER**: 0001213900-25-067336

**CONFORMED SUBMISSION TYPE**: S-3MEF

**PUBLIC DOCUMENT COUNT**: 6

**FILED AS OF DATE**: 20250724

**DATE AS OF CHANGE**: 20250724

**EFFECTIVENESS DATE**: 20250724

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Incannex Healthcare Inc.
- **CENTRAL INDEX KEY:** 0001873875
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** S-3MEF
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288921
- **FILM NUMBER:** 251146961

**BUSINESS ADDRESS:**
- **STREET 1:** 8 CENTURY CIRCUIT
- **STREET 2:** STE. 105
- **CITY:** NORWEST NSW
- **STATE:** C3
- **ZIP:** 2153
- **BUSINESS PHONE:** 61 409 840 786

**MAIL ADDRESS:**
- **STREET 1:** 8 CENTURY CIRCUIT
- **STREET 2:** STE. 105
- **CITY:** NORWEST NSW
- **STATE:** C3
- **ZIP:** 2153

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Incannex Healthcare Ltd
- **DATE OF NAME CHANGE:** 20210720

**As filed with the Securities and Exchange Commission on July 24, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM S-3**

**REGISTRATION STATEMENT**

***UNDER***

***THE SECURITIES ACT OF 1933***

**INCANNEX HEALTHCARE INC.**

(Exact Name of Registrant as Specified in Its Charter)

---

| | |
|:---|:---|
| <br> **Delaware** | **93-2403210** |
| (State or other jurisdiction of<br> incorporation or organization) | (IRS Employer<br> Identification No.) |

---

**Suite 105, 8 Century Circuit Norwest,<br> NSW 2153 Australia**

**+61 409 840 786**

(Address, including zip code, and telephone number, including area code, of Registrant's principal executive offices)

**Joel Latham**

**President and Chief Executive Officer**

**Incannex Healthcare Inc.**

**Suite 105, 8 Century Circuit Norwest, NSW 2153 Australia**

**+61 409 840 786**

(Name, address, including zip code, and telephone number, including area code, of agent for service)

**Copies to:**

**Scott M. Stanton, Esq.**

**Melanie Ruthrauff Levy, Esq.**

**Jason Miller, Esq.**

**Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.**

**San Diego, CA 92130**

**Tel: (858) 314-1500**

**Approximate date of commencement of proposed sale to the public:** From time to time after the effective date of this registration statement.

If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, as amended, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☒ 333-283028

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**This registration statement shall become effective upon filing in accordance with Rule 462(b) promulgated under the Securities Act of 1933, as amended.**

**EXPLANATORY NOTE AND INCORPORATION OF CERTAIN INFORMATION BY REFERENCE**

Pursuant to Rule 462(b) under the Securities Act of 1933, as amended, Incannex Healthcare Inc. (the "Registrant"), is filing this Registration Statement on Form S-3 (this "Registration Statement") with the Securities and Exchange Commission (the "Commission"). This Registration Statement relates to the public offering of securities contemplated by the Registration Statement on [Form S-3](https://www.sec.gov/Archives/edgar/data/1873875/000121390024094998/ea0219809-s3_incannex.htm) (File No. 333-283028) (the "Prior Registration Statement"), which the Registrant filed with the Commission on November 6, 2024 and which the Commission declared effective on November 22, 2024.

The Registrant is filing this Registration Statement for the sole purpose of increasing the aggregate amount of securities registered for issuance by the Registrant by a proposed additional aggregate offering price of $13,469,250. The additional securities that are being registered for issuance and sale are in an amount and at a price that together represent no more than 20% of the maximum aggregate offering price of unsold securities under the Prior Registration Statement. The information set forth in the Prior Registration Statement and all exhibits to the Prior Registration Statement are hereby incorporated by reference into this Registration Statement.

The required opinions and consents are listed on an Exhibit Index below and filed herewith or incorporated by reference herein.

**PART II**

**INFORMATION NOT REQUIRED IN PROSPECTUS**

**Item 16. Exhibits**

The following documents are filed as part of this registration statement on Form S-3:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 5.1 | [Opinion of Mintz, Levin, Cohn, Ferris, Glovksy and Popeo, P.C.](ea025004601ex5-1_incannex.htm) |
| 23.1 | [Consent of Mintz, Levin, Cohn, Ferris, Glovksy and Popeo, P.C. (included in Exhibit 5.1 to this Registration Statement).](ea025004601ex5-1_incannex.htm) |
| 23.2 | [Consent of Grant Thornton, independent registered public accounting firm of Incannex Healthcare Inc.](ea025004601ex23-2_incannex.htm) |
| 24.1 | [Power of Attorney (incorporated by reference to Exhibit 24.1 to the Prior Registration Statement).](https://www.sec.gov/Archives/edgar/data/1873875/000101376225001587/ea0235305-s3_incannex.htm#poa_001) |
| 107 | [Filing Fee Table.](ea025004601ex-fee_incannex.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Melbourne, Australia, on July 24, 2025.

---

| | |
|:---|:---|
| **INCANNEX HEALTHCARE INC.** | **INCANNEX HEALTHCARE INC.** |
| By: | /s/ Joel Latham |
| Name: | Joel Latham |
| Title: | Chief Executive Officer, President and Director (principal executive officer) |

---

---

| | |
|:---|:---|
| By: | /s/ Joseph Swan |
| Name: | Joseph Swan |
| Title: | Chief Financial Officer <br> (principal financial officer and accounting officer) |

---

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Joel Latham | Chief Executive Officer, President and Director<br> (principal executive officer) | July 24, 2025 |
| Joel Latham | Chief Executive Officer, President and Director<br> (principal executive officer) |  |
| /s/ Joseph Swan | Chief Financial Officer | July 24, 2025 |
| Joseph Swan | (principal financial officer and accounting officer) |  |
| /s/ Troy Valentine | Director | July 24, 2025 |
| Troy Valentine |  |  |
| /s/ Peter Widdows | Director | July 24, 2025 |
| Peter Widdows |  |  |
| /s/ George Anastassov | Director | July 24, 2025 |
| George Anastassov |  |  |
| /s/ Robert Clark | Director | July 24, 2025 |
| Robert Clark |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

---

| | |
|:---|:---|
| ![](ex5-1_001.jpg) | 3580 Carmel Mountain Road, Ste 300<br> San Diego, CA 92130<br> 858 314 1500<br> mintz.com |

---

July 24, 2025

Incannex Healthcare Inc.

Suite 105, 8 Century Circuit

Norwest, NSW 2153 Australia

Ladies and Gentlemen:

We have acted as legal counsel to Incannex Healthcare Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the preparation and filing with the Securities and Exchange Commission (the "<u>Commission</u>") of a Registration Statement on Form S-3 (the "<u>462(b) Registration Statement</u>"), pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"). The 462(b) Registration Statement incorporates by reference the Company's Registration Statement on Form S-3 (File No. 333-283028) filed with the Commission on November 6, 2024, under the Securities Act, and declared effective by the Commission on November 22, 2024 (the "<u>Initial Registration Statement</u>" and together with the 462(b) Registration Statement, the "<u>Registration Statement</u>"). This opinion is furnished to you in connection with your filing of the 462(b) Registration Statement, which is registering the offering by the Company of up to $13,469,250 of the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) common stock, $0.0001 par value per share (the "<u>Common Stock</u>");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) preferred stock, $0.0001 par value per share (the "<u>Preferred Stock</u>");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) debt securities, in one or more series (the "<u>Debt Securities</u>"), which may be issued pursuant to an indenture to be dated on or about the date of the first issuance of Debt Securities thereunder, by and between the Company and a trustee to be selected by the Company, in the form attached as Exhibit 4.6 to the Initial Registration Statement, as such indenture may be amended or supplemented from time to time (the "<u>Indenture</u>");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) warrants to purchase Common Stock, Preferred Stock, and/or Debt Securities (the "<u>Warrants</u>"), which may be issued under warrant agreements, to be dated on or about the date of the first issuance of the applicable Warrants thereunder, by and between the Company and a warrant agent to be selected by the Company (each, a "<u>Warrant Agreement</u>"); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) units comprised of one or more Debt Securities, shares of Common Stock, shares of Preferred Stock, and/or Warrants, in any combination (the "<u>Units</u>"), which may be issued under unit agreements, to be dated on or about the date of the first issuance of the applicable Units thereunder, by and between the Company and a unit agent to be selected by the Company (each, a "<u>Unit Agreement</u>").

BOSTON LOS ANGELES MIAMI NEW YORK SAN DIEGO SAN FRANCISCO TORONTO WASHINGTON

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C.

**MINTZ**

July 24, 2025

![](ex5-1_002.jpg)

The Common Stock, the Preferred Stock, the Debt Securities, the Warrants, and the Units are collectively referred to herein as the "Securities." The Registration Statement relates to the registration of the Securities to be offered and sold by the Company from time to time on a delayed or continuous basis pursuant to Rule 415 under the Securities Act. All capitalized terms used herein and not otherwise defined shall have the respective meanings given to them in the Registration Statement.

In connection with this opinion, we have examined the Company's amended and restated certificate of incorporation, and the amended and restated bylaws, each as currently in effect; such other records of the corporate proceedings of the Company and certificates of the Company's officers as we have deemed relevant; and the Registration Statement and the exhibits thereto.

In our examination, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all documents submitted to us as originals, the conformity to original documents of all documents submitted to us as certified or photostatic copies and the authenticity of the originals of such copies.

In our capacity as counsel to the Company in connection with such registration, we are familiar with the proceedings taken and proposed to be taken by the Company in connection with the authorization and issuance of the Securities. For purposes of this opinion, we have assumed that such proceedings will be timely and properly completed, in accordance with all requirements of applicable federal and Delaware laws, in the manner presently proposed.

The opinions set forth below are subject to the following exceptions, limitations and qualifications: (i) the effect of bankruptcy, insolvency, reorganization, fraudulent conveyance, moratorium or other similar laws now or hereafter in effect relating to or affecting the rights and remedies of creditors; (ii) the effect of general principles of equity, whether enforcement is considered in a proceeding in equity or at law, and the discretion of the court before which any proceeding therefor may be brought; (iii) the unenforceability under certain circumstances under law or court decisions of provisions providing for the indemnification of, or contribution to, a party with respect to a liability where such indemnification or contribution is contrary to public policy; (iv) we express no opinion concerning the enforceability of any waiver of rights or defenses with respect to stay, extension or usury laws; and (v) we express no opinion with respect to whether acceleration of any Debt Securities may affect the ability to collect any portion of the stated principal amount thereof which might be determined to constitute unearned interest thereon.

**MINTZ**

July 24, 2025

![](ex5-1_002.jpg)

We have relied as to certain matters on information obtained from public officials, officers of the Company, and other sources believed by us to be responsible and we have assumed that the Indenture will be duly authorized, executed, and delivered by the respective trustees thereunder and the Warrant Agreement and Unit Agreement will be duly authorized, executed, and delivered by the warrant agent and unit agent, respectively, thereunder. With respect to our opinion as to the Common Stock and Securities convertible into or exercisable for shares of Common Stock, we have assumed that, at the time of issuance and sale, a sufficient number of shares of Common Stock are authorized and available for issuance under the Company's amended and restated certificate of incorporation as then in effect and that the consideration for the issuance and sale of the Common Stock (or Preferred Stock, Debt Securities convertible into Common Stock or Warrants exercisable for Common Stock or any Units of such Securities) is in an amount that is not less than the par value of the Common Stock. With respect to our opinion as to the Preferred Stock and Securities convertible into or exercisable for shares of Preferred Stock, we have assumed that, at the time of issuance and sale, a sufficient number of shares of Preferred Stock are authorized, designated and available for issuance and that the consideration for the issuance and sale of the Preferred Stock (or Debt Securities convertible into Preferred Stock or Warrants exercisable for Preferred Stock or any Units of such Securities) is in an amount that is not less than the par value of the Preferred Stock. We have also assumed that any Warrants, and Units offered under the Registration Statement, and the related Warrant Agreement and Unit Agreement, as applicable, will be executed in the forms to be filed as exhibits to the Registration Statement or incorporated by reference therein. We have not independently verified any of the foregoing assumptions.

It is understood that this opinion is to be used only in connection with the offer and sale of Securities while the Registration Statement is effective under the Securities Act.

Members of our firm are admitted to the Bar of the Commonwealth of Massachusetts, State of California and the State of New York, and we do not express any opinion as to the laws of any other jurisdiction other than the General Corporation Law of the State of Delaware, the United States federal laws and, as to the Debt Securities constituting valid and legally binding obligations of the Company, the laws of the State of New York. Without limiting the generality of the foregoing, we express no opinion with respect to (i) the qualification of the Securities under the securities or blue sky laws of any state or any foreign jurisdiction or (ii) the compliance with any federal or state law, rule or regulation relating to securities, or to the sale or issuance thereof.

Please note that we are opining only as to the matters expressly set forth herein, and no opinion should be inferred as to any other matters. The Securities may be issued from time to time on a delayed or continuous basis, but this opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein.

**MINTZ**

July 24, 2025

![](ex5-1_002.jpg)

Based upon the foregoing, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. With respect to the Common Stock, when (i) specifically authorized for issuance by the Company's board of directors or an authorized committee thereof (the "<u>Authorizing Resolutions</u>"), (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) an appropriate prospectus supplement with respect to the applicable shares of Common Stock has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (iv) if the applicable shares of Common Stock are to be sold pursuant to a purchase, underwriting or similar agreement (an "<u>Underwriting Agreement</u>"), such Underwriting Agreement with respect to the applicable shares of Common Stock in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (v) the terms of issuance and sale of the Common Stock have been duly established in conformity with the Company's then operative certificate of incorporation and bylaws and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vi) the Common Stock has been issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (vii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Common Stock will be validly issued, fully paid and non-assessable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. With respect to the Preferred Stock, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) an appropriate prospectus supplement with respect to the applicable shares of Preferred Stock has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (iv) if the applicable shares of Preferred Stock are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable shares of Preferred Stock in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (v) an appropriate certificate or certificates of amendment or designation relating to a class or series of the Preferred Stock to be sold under the Registration Statement has been duly authorized and adopted and filed with the Secretary of State of the State of Delaware prior to the issuance of the Preferred Stock, (vi) the terms of issuance and sale of shares of such class or series of Preferred Stock have been duly established in conformity with the Company's then operative certificate of incorporation and bylaws and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) shares of such class or series of Preferred Stock have been duly issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (viii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Preferred Stock will be validly issued, fully paid and non-assessable.

**MINTZ**

July 24, 2025

![](ex5-1_002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. With respect to the Debt Securities, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) the Indenture has been duly authorized, executed and delivered by the Company, (iv) an appropriate prospectus supplement with respect to the applicable Debt Securities has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (v) if the applicable Debt Securities are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable Debt Securities in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto; (vi) the terms of the Debt Securities and of their issuance and sale have been duly established in conformity with the Indenture and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) such Debt Securities have been duly executed and authenticated in accordance with the Indenture and issued and sold as contemplated in the Registration Statement and the prospectus included therein, (viii) Indenture relating to the Debt Securities has been qualified under the Trust Indenture Act of 1939, as amended, and (ix) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Debt Securities will constitute valid and legally binding obligations of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. With respect to the Warrants, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) the Warrant Agreement relating to the Warrants has been duly authorized, executed, and delivered by the Company, (iv) an appropriate prospectus supplement with respect to the applicable Warrants has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (v) if the applicable Warrants are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable Warrants in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (vi) the terms of the Warrants and of their issuance and sale have been duly established in conformity with the Warrant Agreement and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) the Warrants have been duly executed and countersigned in accordance with the Warrant Agreement and issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (viii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Warrants will constitute valid and legally binding obligations of the Company.

**MINTZ**

July 24, 2025

![](ex5-1_002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. With respect to the Units, when (i) specifically authorized for issuance by the Authorizing Resolutions, (ii) the Registration Statement, as finally amended (including all post-effective amendments), has become effective under the Securities Act, (iii) the Unit Agreement relating to the Units has been duly authorized, executed, and delivered by the Company, (iv) an appropriate prospectus supplement with respect to the applicable Units has been prepared, delivered and filed in compliance with the Securities Act and the applicable rules and regulations thereunder, (v) if the applicable Units are to be sold pursuant to an Underwriting Agreement, such Underwriting Agreement with respect to the applicable Units in the form filed as an exhibit to the Registration Statement, any post-effective amendment thereto or to a Current Report on Form 8-K, has been duly authorized, executed and delivered by the Company and the other parties thereto, (vi) the terms of the Units and of their issuance and sale have been duly established in conformity with the Unit Agreement and do not violate any applicable law or result in a default under or breach of any agreement or instrument binding upon the Company and comply with any requirement or restriction imposed by any court or governmental body having jurisdiction over the Company, (vii) the Units have been duly executed and countersigned in accordance with the Unit Agreement and issued and sold as contemplated by the Registration Statement and the prospectus included therein, and (viii) the Company has received the consideration provided for in the Authorizing Resolutions and, if applicable, the Underwriting Agreement, the Units will constitute valid and legally binding obligations of the Company.

We understand that the Company wishes to file this opinion with the Commission as an exhibit to the 462(b) Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation S-K promulgated under the Securities Act and to reference the firm's name under the caption "Legal Matters" in the prospectus which forms part of the 462(b) Registration Statement, and we hereby consent thereto. In giving this consent, we do not admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations of the Commission promulgated thereunder.

---

| |
|:---|
| Very truly yours, |
| /s/ Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |
| Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. |

---

## Exhibit 23.2

**Exhibit 23.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We have issued our report dated September 30, 2024 with respect to the consolidated financial statements of Incannex Healthcare Inc. included in the Annual Report on Form 10-K for the year ended June 30, 2024, which are incorporated by reference in this Registration Statement. We consent to the incorporation by reference of the aforementioned report in this Registration Statement.

/s/ GRANT THORNTON AUDIT PTY LTD

Perth, Australia

July 24, 2025

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table**

Form S-3

(Form Type)

Incannex Healthcare Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

---

| | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security Class Title** | **Fee Calculation or Carry Forward Rule** | **Amount** <br> **Registered** |  | **Proposed** <br> **Maximum Offering Price Per Unit** |  | **Maximum Aggregate** <br> **Offering Price**  |  | **Fee Rate** | **Amount of Registration** <br> **Fee** |
| **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** | **Newly Registered Securities** |
| Fees to be Paid | Equity | Common Stock, $0.0001 par value per share | 457(0) |  | (1) |  | (1) |  | (1) |  |  |
| Fees to be Paid | Equity | Preferred Stock, $0.0001 par value per share | 457(0) |  | (1) |  | (1) |  | (1) |  |  |
| Fees to be Paid | Debt | Debt Securities | 457(0) |  | (1) |  | (1) |  | (1) |  |  |
| Fees to be Paid | Equity | Warrants | 457(0) |  | (1) |  | (1) |  | (1) |  |  |
| Fees to be Paid | Equity | Units | 457(0) |  | (1) |  | (1) |  | (1) |  |  |
| Fees to be Paid | Unallocated (universal Shelf) | (1) | 457(0) |  | (1) |  | (1) | $13469250 |  | **0.00015310** | $2062.15 |
| **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** | **Carry Forward Securities** |
| Carry Forward Securities |  |  |  |  |  |  |  |  |  |  |  |
|  |  | Total Offering Amounts |  |  |  |  |  | $13469250 |  |  | $2062.15 |
|  |  | Total Fees Previously Paid |  |  |  |  |  |  |  |  | - |
|  |  | Total Fee Offset |  |  |  |  |  |  |  |  | - |
|  |  | Net Fee Due |  |  |  |  |  |  |  |  | $2062.15 |

---

(1) The registrant previously registered the offer and sale of
certain securities, including its common stock, par value $0.0001 per share (the "Common Stock"), preferred stock, par value
$0.0001 per share (the "Preferred Stock"), debt securities, warrants to purchase Common Stock, Preferred Stock and/or debt
securities, and units, having a proposed maximum aggregate offering price of $150,000,000 pursuant to a Registration Statement on Form
S-3 (File No. 333- 283028) (the "Initial Registration Statement"), which was
initially filed on November 6, 2024 and declared effective by the Securities and Exchange
Commission on November 22, 2024 . As of the date hereof, $86,530,750 of such securities remains
unsold under the Initial Registration Statement. In accordance with Rule 462(b) under the Securities Act of 1933, as amended (the "Securities
Act"), and General Instruction IV(A) of Form S-3, the registrant is hereby registering the offer and sale of an additional $13,469,250
aggregate maximum amount of its securities. The additional amount of securities that is being registered for offer and sale represents
no more than 20% of the maximum aggregate offering price of the remaining securities available to be sold under the Initial Registration
Statement.